ArticleiScience2026

Cost-effectiveness of first-line encorafenib plus cetuximab with mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer.

Yamin Shu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.